Due to the actions GSK-3 has over the expression of Nrf2 target genes, current research has led to the development of novel multitargeted therapeutics that both inhibit GSK-3β and induce Nrf2 for the treatment of inflammatory diseases, such as Parkinson’s and Alzheimer’s disease [114,115]. Here, NFE2L2 is linked to early-onset autosomal dominant Alzheimer disease.